Stratasan

Canaccord Genuity Advises Stratasan on its Acquisition by Syntellis Performance Solutions, a Portfolio Company of Madison Dearborn Partners and Thoma Bravo

Acquisition accelerates data-driven, comprehensive decision-making for healthcare organizations across the country 

Canaccord Genuity is pleased to announce that it advised Stratasan, LLC, a Nashville-based provider of healthcare market intelligence software solutions and a portfolio company of Fulcrum Equity Partners, Frist Cressey Ventures, and Blue Heron Capital, on its acquisition by Syntellis Performance Solutions, LLC, the market leader in enterprise performance management (“EPM”) solutions and a portfolio company of Madison Dearborn Partners and Thoma Bravo.

Stratasan’s comprehensive suite of market intelligence software solutions provides critical insights that inform strategic growth priorities and initiatives in clients’ core and target markets. With differentiated data aggregation and analytics capabilities that support market analysis, strategic growth planning, physician referral alignment, payor reimbursement optimization and data transparency, Stratasan enables its clients to execute effectively and efficiently on their growth strategies, capitalize on emerging market opportunities and address existing pain-points and gaps. While the Company initially focused on establishing a strong foothold in the acute care space and currently supports more than 1,000 hospital facilities, its solutions have broad applications across the entire healthcare ecosystem, driving Stratasan’s recent expansion into the payor, ancillary care organization, consulting and hospital association markets.

Syntellis, which was formed in 2020 through the spin-off of Kaufman Hall’s software division, delivers purpose-built EPM software, data and intelligence solutions to healthcare, higher education and financial institutions. Syntellis’s healthcare solutions provide hospitals and health systems financial planning and enterprise decision support software to optimize financial, clinical and operational performance.

Together, Syntellis and Stratasan are positioned to deliver intelligence and insights to help healthcare leaders determine where, when and how to grow. With the addition of Stratasan’s diverse customer base, Syntellis strengthens its position in the healthcare vertical and expands its reach beyond the acute care market. Stratasan’s market-based insights coupled with Syntellis’s internal-focused planning and decision support tools will help create a performance improvement platform built to optimize financial, operational and strategic results across the healthcare landscape.

This transaction represents Canaccord’s eighth healthcare analytics and intelligence M&A transaction since 2021 following Apollo Intelligence’s acquisition by Frazier Healthcare Partners, DMD’s acquisition by IQVIA, VisiQuate’s investment from Sixth Street Growth, PulsePoint’s acquisition by Internet Brands, ChartWise Medical Systems’ acquisition by Iodine Software, Marketware’s acquisition by Medsphere, and Mavens’ acquisition by Komodo Health.

Canaccord Genuity, with a team led by Dudley Baker and Fred Fang, served as the exclusive financial advisor to Stratasan.